Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO
'Nanofludics' Accelerates Antibody Discovery
Executive Summary
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
You may also be interested in...
J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.